Bajaj Healthcare shares hit 10% upper circuit as market reassesses profits in Q3FY25 earnings

Bajaj Healthcare shares hit 10% upper circuit as market reassesses profits in Q3FY25 earnings

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Bajaj Healthcare shares hit 10 percent upper circuit on February 12, a day after trading lower on the announcement of its Q3FY25 results. The shares are trading at Rs 650.10 as of 1:21 pm.

Read about Stock Market updates LIVE

The pharmaceutical company recorded profits in Q3 FY25, reaching a figure of Rs 11.7 crore as compared to a net loss of Rs 2.2 crore in the corresponding quarter of last fiscal. Meanwhile, its revenue from operations rose to Rs 122.8 crore, marking a gain of 13.1 percent on a year-over-year basis. Last year, the third quarter had seen the company's revenue from operations at Rs 108.6 crore. The uptrend this quarter was said to be a result of higher demand for its active pharmaceutical ingredients (APIs) and bulk drugs.

The company's EBITDA was at Rs 21.7 crore for the period under review, marking 10.7 percent rise from Rs 19.6 crore in Q3FY24. Although the EBITDA margin came at a slight decline, to 17.7 percent as compared to 18.1 percent in the previous year.

Earlier this week, a Bloomberg report also revealed that the Bajaj Group plans to invest Rs 100 billion (approximately $1.1 billion) to establish a hospital chain. The intent is to develop a network of hospitals, including both affordable and high-end facilities, as the report further revealed.

Among the recent developments, Bajaj Healthcare had also announced receiving exclusive rights for manufacturing, distribution and sales of the finished formulation of the Product Magnesium L Threonate (Magtein) in India from the rights holder, Threotech LLC. Last week, it had also received an approval from the Drug Controller General of India to manufacture a treatment drug of hallucinations and delusions for Parkinson’s disease.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.